Revatio (sildenafil 20 mg) directly improves blood flow in the pulmonary arteries, thereby easing the strain on the heart in patients with Pulmonary Arterial Hypertension (PAH).
It achieves this by inhibiting phosphodiesterase type 5 (PDE5), leading to increased levels of cyclic guanosine monophosphate (cGMP). Higher cGMP levels relax and widen blood vessels, reducing pulmonary vascular resistance.
Revatio’s impact on PAH management extends beyond simple vasodilation. Studies show it can improve exercise capacity, a key indicator of PAH severity. Patients often report increased ability to perform daily activities.
However, Revatio’s efficacy varies among individuals. Regular monitoring of blood pressure and potential side effects, such as headaches and flushing, are crucial. Your physician will adjust the dosage based on your response and tolerance.
| Mechanism | PDE5 inhibition, increased cGMP |
| Primary Effect | Pulmonary vasodilation |
| Clinical Benefit | Improved exercise capacity, enhanced quality of life |
| Monitoring | Blood pressure, side effects |
Remember, Revatio is part of a broader PAH treatment strategy. Your doctor may prescribe additional medications, such as oxygen therapy or other pulmonary vasodilators, depending on your individual needs. Open communication with your healthcare provider is essential for optimal management of your PAH.
